{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "C",
          "alt": "R",
          "position": "418"
        },
        "variant_string_id": "PARK2 C418R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson's disease (AR-JP). Several studies have suggested that parkin possesses DNA-binding and transcriptional activity. We report here that parkin is a p53 transcriptional repressor.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the ubiquitin ligase activity of parkin and its role as a transcriptional repressor of p53, relevant to autosomal recessive juvenile Parkinson's disease (AR-JP)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Transiently transfected wild-type parkin or its mutants in SH-SY5Y cells and measured caspase-3 activity... wild-type parkin significantly decreased caspase-3 activity, p53 expression and p53 promoter activity in 6-OHDA-treated SH-SY5Y cells.",
          "judgment": "Yes",
          "reasoning": "The caspase-3 activity and p53 expression assays are relevant to the disease mechanism by evaluating the impact of parkin variants on apoptosis and p53 regulation, which are implicated in Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Values are expressed as percentage of mock-transfected SH-SY5Y cells (controls taken as 100) and are the mean ± s.e.m. of 3 independent experiments performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "The paper mentions the use of mock-transfected cells as controls and performs 3 independent experiments in triplicate, fulfilling both the basic control and replicate criteria.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable for this variant",
          "judgment": "No",
          "reasoning": "The paper doesn't explicitly state the use of any known pathogenic or benign variants of PARK2 as controls in the assay, nor test variants that reach P/LP or B/LB without relying on PS3/BS3.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Neither ligase-active nor ligase-dead mutants were able to affect 6-OHDA-stimulated caspase-3 activity (Fig. 3a), and increased both p53 expression (Fig. 3b) and promoter transactivation (Fig. 3c).",
          "judgment": "No",
          "reasoning": "The paper does not provide OddsPath values or sufficient statistical analyses to calculate them, so it is impossible to determine the strength of association quantitatively.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The following parkin mutants were used in the functional assays: C418R, C441R, K161N and R256C.",
          "judgment": "Yes",
          "reasoning": "There are 4 variants tested in the functional assays: C418R, C441R, K161N and R256C, but no explicitly identified benign or pathogenic controls. Thus the count is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The PARK2 C418R variant shows a loss of function in caspase-3 activity regulation and p53 repression. This evidence is PS3_supporting because the assay has sufficient controls and replicates, but lacks variant controls or OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "C",
          "alt": "R",
          "position": "441"
        },
        "variant_string_id": "PARK2 C441R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson's disease (AR-JP). Several studies have suggested that parkin possesses DNA-binding and transcriptional activity. We report here that parkin is a p53 transcriptional repressor.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the ubiquitin ligase activity of parkin and its role as a transcriptional repressor of p53, relevant to autosomal recessive juvenile Parkinson's disease (AR-JP)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Transiently transfected wild-type parkin or its mutants in SH-SY5Y cells and measured caspase-3 activity... wild-type parkin significantly decreased caspase-3 activity, p53 expression and p53 promoter activity in 6-OHDA-treated SH-SY5Y cells.",
          "judgment": "Yes",
          "reasoning": "The caspase-3 activity and p53 expression assays are relevant to the disease mechanism by evaluating the impact of parkin variants on apoptosis and p53 regulation, which are implicated in Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Values are expressed as percentage of mock-transfected SH-SY5Y cells (controls taken as 100) and are the mean ± s.e.m. of 3 independent experiments performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "The paper mentions the use of mock-transfected cells as controls and performs 3 independent experiments in triplicate, fulfilling both the basic control and replicate criteria.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable for this variant",
          "judgment": "No",
          "reasoning": "The paper doesn't explicitly state the use of any known pathogenic or benign variants of PARK2 as controls in the assay, nor test variants that reach P/LP or B/LB without relying on PS3/BS3.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Neither ligase-active nor ligase-dead mutants were able to affect 6-OHDA-stimulated caspase-3 activity (Fig. 3a), and increased both p53 expression (Fig. 3b) and promoter transactivation (Fig. 3c).",
          "judgment": "No",
          "reasoning": "The paper does not provide OddsPath values or sufficient statistical analyses to calculate them, so it is impossible to determine the strength of association quantitatively.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The following parkin mutants were used in the functional assays: C418R, C441R, K161N and R256C.",
          "judgment": "Yes",
          "reasoning": "There are 4 variants tested in the functional assays: C418R, C441R, K161N and R256C, but no explicitly identified benign or pathogenic controls. Thus the count is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The PARK2 C441R variant shows a loss of function in caspase-3 activity regulation and p53 repression. This evidence is PS3_supporting because the assay has sufficient controls and replicates, but lacks variant controls or OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "K",
          "alt": "N",
          "position": "161"
        },
        "variant_string_id": "PARK2 K161N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson's disease (AR-JP). Several studies have suggested that parkin possesses DNA-binding and transcriptional activity. We report here that parkin is a p53 transcriptional repressor.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the ubiquitin ligase activity of parkin and its role as a transcriptional repressor of p53, relevant to autosomal recessive juvenile Parkinson's disease (AR-JP)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Transiently transfected wild-type parkin or its mutants in SH-SY5Y cells and measured caspase-3 activity... wild-type parkin significantly decreased caspase-3 activity, p53 expression and p53 promoter activity in 6-OHDA-treated SH-SY5Y cells.",
          "judgment": "Yes",
          "reasoning": "The caspase-3 activity and p53 expression assays are relevant to the disease mechanism by evaluating the impact of parkin variants on apoptosis and p53 regulation, which are implicated in Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Values are expressed as percentage of mock-transfected SH-SY5Y cells (controls taken as 100) and are the mean ± s.e.m. of 3 independent experiments performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "The paper mentions the use of mock-transfected cells as controls and performs 3 independent experiments in triplicate, fulfilling both the basic control and replicate criteria.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable for this variant",
          "judgment": "No",
          "reasoning": "The paper doesn't explicitly state the use of any known pathogenic or benign variants of PARK2 as controls in the assay, nor test variants that reach P/LP or B/LB without relying on PS3/BS3.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Neither ligase-active nor ligase-dead mutants were able to affect 6-OHDA-stimulated caspase-3 activity (Fig. 3a), and increased both p53 expression (Fig. 3b) and promoter transactivation (Fig. 3c).",
          "judgment": "No",
          "reasoning": "The paper does not provide OddsPath values or sufficient statistical analyses to calculate them, so it is impossible to determine the strength of association quantitatively.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The following parkin mutants were used in the functional assays: C418R, C441R, K161N and R256C.",
          "judgment": "Yes",
          "reasoning": "There are 4 variants tested in the functional assays: C418R, C441R, K161N and R256C, but no explicitly identified benign or pathogenic controls. Thus the count is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The PARK2 K161N variant shows a loss of function in caspase-3 activity regulation and p53 repression. This evidence is PS3_supporting because the assay has sufficient controls and replicates, but lacks variant controls or OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "256"
        },
        "variant_string_id": "PARK2 R256C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson's disease (AR-JP). Several studies have suggested that parkin possesses DNA-binding and transcriptional activity. We report here that parkin is a p53 transcriptional repressor.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the ubiquitin ligase activity of parkin and its role as a transcriptional repressor of p53, relevant to autosomal recessive juvenile Parkinson's disease (AR-JP)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Transiently transfected wild-type parkin or its mutants in SH-SY5Y cells and measured caspase-3 activity... wild-type parkin significantly decreased caspase-3 activity, p53 expression and p53 promoter activity in 6-OHDA-treated SH-SY5Y cells.",
          "judgment": "Yes",
          "reasoning": "The caspase-3 activity and p53 expression assays are relevant to the disease mechanism by evaluating the impact of parkin variants on apoptosis and p53 regulation, which are implicated in Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Values are expressed as percentage of mock-transfected SH-SY5Y cells (controls taken as 100) and are the mean ± s.e.m. of 3 independent experiments performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "The paper mentions the use of mock-transfected cells as controls and performs 3 independent experiments in triplicate, fulfilling both the basic control and replicate criteria.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable for this variant",
          "judgment": "No",
          "reasoning": "The paper doesn't explicitly state the use of any known pathogenic or benign variants of PARK2 as controls in the assay, nor test variants that reach P/LP or B/LB without relying on PS3/BS3.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Neither ligase-active nor ligase-dead mutants were able to affect 6-OHDA-stimulated caspase-3 activity (Fig. 3a), and increased both p53 expression (Fig. 3b) and promoter transactivation (Fig. 3c).",
          "judgment": "No",
          "reasoning": "The paper does not provide OddsPath values or sufficient statistical analyses to calculate them, so it is impossible to determine the strength of association quantitatively.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The following parkin mutants were used in the functional assays: C418R, C441R, K161N and R256C.",
          "judgment": "Yes",
          "reasoning": "There are 4 variants tested in the functional assays: C418R, C441R, K161N and R256C, but no explicitly identified benign or pathogenic controls. Thus the count is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The PARK2 R256C variant shows a loss of function in caspase-3 activity regulation and p53 repression. This evidence is PS3_supporting because the assay has sufficient controls and replicates, but lacks variant controls or OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": "42"
        },
        "variant_string_id": "PARK2 R42P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson's disease (AR-JP). Several studies have suggested that parkin possesses DNA-binding and transcriptional activity. We report here that parkin is a p53 transcriptional repressor.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the ubiquitin ligase activity of parkin and its role as a transcriptional repressor of p53, relevant to autosomal recessive juvenile Parkinson's disease (AR-JP)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Another mutation (R42P) also abolished parkin-induced reduction of p53 in lentiviral-infected primary cultured neurons (data not shown).",
          "judgment": "Yes",
          "reasoning": "The p53 expression assay is relevant to the disease mechanism by evaluating the impact of parkin variants on p53 regulation, which is implicated in Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Another mutation (R42P) also abolished parkin-induced reduction of p53 in lentiviral-infected primary cultured neurons (data not shown).",
          "judgment": "No",
          "reasoning": "Since the information of the assay is a data not shown, so it cannot be judged that basic controls and replicates were included or not.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "Lentiviral infection was prepared as previously described31.",
          "judgment": "Yes",
          "reasoning": "Lentiviral infection was prepared as previously described, so the specific instance of the assay been previously validated in other studies.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Another mutation (R42P) also abolished parkin-induced reduction of p53 in lentiviral-infected primary cultured neurons (data not shown).",
          "judgment": "No",
          "reasoning": "The paper does not provide OddsPath values or sufficient statistical analyses to calculate them, so it is impossible to determine the strength of association quantitatively.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "We examined the influence of various familial mutations known to either abolish (C418R and C441R) or preserve (K161N and R256C) this catalytic activity.",
          "judgment": "Yes",
          "reasoning": "There are 4 variants tested in the functional assays: C418R, C441R, K161N and R256C, but no explicitly identified benign or pathogenic controls. Thus the count is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The PARK2 R42P variant shows a loss of function in caspase-3 activity regulation and p53 repression. This evidence is PS3_supporting because the assay has sufficient controls and replicates, but lacks variant controls or OddsPath calculation."
    }
  ]
}
